Organisation paid for research Program year 2023 Source: CMS Open Payments

Usma Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$171,663

53 payments

Through program year 2023, Usma Clinical Research LLC is reported as receiving $171,663 in research payments, across 53 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $3,820 2
2022 Research $27,267 9
2021 Research $61,908 15
2020 Research $66,648 22
2019 Research $12,019 5

Breakdown

Who paid Research payments · program years 2019–2023
  1. AbbVie, Inc. $123,704 34 payments
  2. Allergan Inc. $47,591 17 payments
  3. Pfizer Inc. $368 2 payments
Studies the money was for Research payments · program years 2019–2023
  1. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $51,442 12 payments
  2. M16-100 $41,175 11 payments
  3. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $29,192 9 payments
  4. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $24,624 10 payments
  5. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $12,500 4 payments
  6. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $10,000 2 payments
  7. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) $1,896 2 payments
  8. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $467 1 payment
  9. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $368 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record